Welcome to CDC stacks | Safety of Recombinant VSV–Ebola Virus Vaccine Vector in Pigs - 29339 | Emerging Infectious Diseases
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
Safety of Recombinant VSV–Ebola Virus Vaccine Vector in Pigs
Filetype[PDF-562.49 KB]


Details:
No Related Documents.
You May Also Like:
  1. Live Virus Vaccines Based on a Vesicular Stomatitis Virus (VSV) Backbone: Standardized Template with Key Considerations for a Risk/Benefit Assessment*
    Personal Author:
    Clarke, David K.; Hendry, R. Michael; Singh, Vidisha; Rose, John K.; Seligman, Stephen J.; Klug, Bettina; Kochhar, Sonali; Mac, Lisa Marie; Carbery, Baevin; Chen, Robert T;
    Corporate Author:
    For the Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG)
    Published:
    Jul 06 2016
    Source:
    Vaccine. 34(51):6597-6609.
    Description:
    The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) was formed to evaluate the safety of live, recombinant viral vaccines incorporating genes from heterologous viral and other microbial pathogens in their genome (so-called "...
    File Type:
    Filetype[PDF - 397.88 KB]
  2. Postexposure Treatment of Marburg Virus Infection
    Personal Author:
    Geisbert, Thomas W.; Hensley, Lisa E.; Geisbert, Joan B.; Leung, Anders; Johnson, Joshua C.; Grolla, Allen; Feldmann, Heinz;
    Published:
    Jul 2010
    Source:
    Emerg Infect Dis. 16(7):1119-1122.
    Description:
    Rhesus monkeys are protected from disease when a recombinant vesicular stomatitis virus-based vaccine is administered 20-30 min after infection with Marburg virus. We protected 5/6 monkeys when this vaccine was given 24 h after challenge; 2/6 animals...
    File Type:
    Filetype[PDF - 264.90 KB]
  3. Single-Dose Replication-Defective VSV-based Nipah Virus Vaccines Provide Protection from Lethal Challenge in Syrian Hamsters
    Personal Author:
    Lo, Michael K.; Bird, Brian H.; Chattopadhyay, Anasuya; Drew, Clifton P.; Martin, Brock E.; Coleman, Joann D.; Rose, John K.; Nichol, Stuart T.; Spiropoulou, Christina F.;
    Published:
    Oct 30 2013
    Source:
    Antiviral Res. 101.
    Description:
    Nipah virus (NiV) continues to cause outbreaks of fatal human encephalitis due to spillover from its bat reservoir. We determined that a single dose of replication-defective vesicular stomatitis virus (VSV)-based vaccine vectors expressing either the...
    File Type:
    Filetype[PDF - 995.25 KB]
  4. Vesicular Stomatitis Virus–Based Vaccines against Lassa and Ebola Viruses
    Personal Author:
    Marzi, Andrea; Feldmann, Friederike; Geisbert, Thomas W.; Feldmann, Heinz; Safronetz, David;
    Published:
    Feb 2015
    Source:
    Emerg Infect Dis. 21(2):305-307.
    Description:
    We demonstrated that previous vaccination with a vesicular stomatitis virus (VSV)-based Lassa virus vaccine does not alter protective efficacy of subsequent vaccination with a VSV-based Ebola virus vaccine. These findings demonstrate the utility of V...
    File Type:
    Filetype[PDF - 315.95 KB]
  5. Virulence of Japanese Encephalitis Virus Genotypes I and III, Taiwan
    Personal Author:
    Fan, Yi-Chin; Lin, Jen-Wei; Liao, Shu-Ying; Chen, Jo-Mei; Chen, Yi-Ying; Chiu, Hsien-Chung; Shih, Chen-Chang; Chen, Chi-Ming; Chang, Ruey-Yi; King, Chwan-Chuen; Chen, Wei-June; Ko, Yi-Ting; Chang, Chao-Chin; Chiou, Shyan-Song;
    Published:
    Nov 2017
    Source:
    Emerg Infect Dis. 23(11):1883-1886.
    Description:
    The virulence of genotype I (GI) Japanese encephalitis virus (JEV) is under debate. We investigated differences in the virulence of GI and GIII JEV by calculating asymptomatic ratios based on serologic studies during GI- and GIII-JEV endemic periods....
    File Type:
    Filetype[PDF - 872.56 KB]